Navigation Links
Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Date:11/18/2013

s. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed pro
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 A study has been ... the Formula 1 track could help to tackle the problem ... (MAT), Stowhealth (a GP surgery based in Stowmarket) and academics ... Simplyhealth. Telemetry technology, which is inspired by equipment ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Six Years Recognizes Breakthrough ... Form of Heart Disease, ABBOTT PARK, Ill., Oct. ... Chicago Innovation Award for its XIENCE V(TM),Everolimus Eluting Coronary ... clinical data, the next-generation drug eluting stent,represents a significant ...
... CAMBRIDGE, Mass., Oct. 28 Peptimmune, Inc., a privately,held biotechnology ... provide an update on the Company,s current phase Ib clinical,trial ... 1. BIO Investor Forum 2008. The presentation will ... at 3:15 p.m. in the Pacific Room at the Palace ...
... DIEGO, Oct. 28 Volcano Corporation,(Nasdaq: VOLC ), ... for the diagnosis and treatment of coronary and peripheral ... results for the,third quarter and first nine months of ... hold a conference call to discuss its financial,results and ...
Cached Biology Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award 2Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award 3Peptimmune Presentations at Upcoming Events 2Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2
(Date:4/23/2014)... in their mid-thirties and forties, face a devastating ... two decades. "Mutant" protein clusters, long blamed for ... the primary focus of therapies in development by ... Prof. Gerardo Lederkremer and Dr. Julia Leitman of ... Immunology, in collaboration with Prof. Ulrich Hartl of ...
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23 2014) ... human neural stem cells (hNSCs) into the brains ... differentiation after 22 and 24 months found that ... months and did not cause tumors. , The ... of Cell Transplantation but is currently ...
(Date:4/23/2014)... likelihood of an accurate group decision increases with the ... a collective faces a variety of factors as ... researchers report that smaller groups actually tend to make ... focused on only certain pieces of information. , The ... about collective intelligence, or the "wisdom of crowds," wherein ...
Breaking Biology News(10 mins):On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... common, but few studies of lung nodule identification and ... from Kaiser Permanente Southern California identified 7,112 patients who ... within the electronic medical record. Their study ... Association for the Study of Lung Cancer,s (IASLC) ...
... WORCESTER, Mass. A new genetic mutation that causes ... also known as Lou Gehrig,s Disease, has been identified ... the University of Massachusetts Medical School (UMMS). Mutations to ... growth and development of nerve cell axons, is estimated ...
... new study by University of North Carolina School of Medicine ... risk for autism spectrum disorders (ASD) at 12 months received ... In addition, 85 percent of the children found to be ... Year Inventory (FYI), a 63-item questionnaire filled out by their ...
Cached Biology News:UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3Questionnaire completed by parents may help identify 1-year-olds at risk for autism 2
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
prototype Nco I...
Biology Products: